Derma Sciences to Hold Second Quarter Financial Results Conference Call on August 12th

Before you go, we thought you'd like these...
Before you go close icon

Derma Sciences to Hold Second Quarter Financial Results Conference Call on August 12th

PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (NAS: DSCI) , a medical device and pharmaceutical company focused on advanced wound care, announced today that it will hold a conference call on August 12, 2013 to discuss the financial results for the second quarter of 2013. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

The conference call is scheduled to begin at 11:00 a.m. EDT (Eastern Daylight Time). The results will be released before the opening of the market that same day.

To access the conference call, U.S.-based listeners should dial 888-563-6275 and international listeners should dial 706-634-7417. All listeners should provide the following passcode: 26708698. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company's website at

Following the conclusion of the conference call, a replay will be available through Aug. 18, 2013 and can be accessed by dialing (855) 859-2056 from within the U.S. or (404) 537-3406 from outside the U.S. All listeners should provide passcode 26708698. The webcast will be available for 30 days.

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products; advanced wound care dressings to address chronic wounds including diabetic ulcers; and traditional dressings. The Company has begun its Phase 3 clinical trial in diabetic foot ulcer healing with DSC127, based on excellent Phase 2 data. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ® is its gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention.

For more information please visit

Derma Sciences, Inc.
John Yetter, 609-514-4744
Chief Financial Officer
LHA, Inc.
Kim Sutton Golodetz, 212-838-3777
Bruce Voss, 310-691-7100

KEYWORDS:   United States  North America  New Jersey


The article Derma Sciences to Hold Second Quarter Financial Results Conference Call on August 12th originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading